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was identiﬁed by an expert panel of oncologists. Only direct costs were considered. 
Costs and outcomes were discounted by an annual rate of 3% (2008). A sensitivity 
analysis was performed on the risk of relapse reduction by FEC-D using the 95% 
conﬁdence intervals around the mean of the DFS hazard ratio observed in the clinical 
trial. RESULTS: Women receiving FEC-D have a greater life expectancy than those 
treated with only FEC (22.83 versus 21.97 years). The average lifetime costs are 
US$9976 for FEC-D and US$7637 for FEC. The incremental cost-effectiveness ratio 
(ICER) was US$2,378 in the base case, varying from US$1,260 to US$30,791 accord-
ing to sensitivity analysis. CONCLUSIONS: FEC-D is associated with an increase in 
life expectancy over FEC. The FEC-D regimen in comparison with FEC fell within 
acceptable ranges of cost-effectiveness. Although there is currently no ofﬁcial cost-
effectiveness threshold in Mexico, we observed an acceptable ICER for the utilization 
of FEC-D at below 3 times the Gross Domestic Product per capita of US$43,200.
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OBJECTIVES: To evaluate the cost-effectiveness of four interventions (Interferon-á 
(IFN), Sunitinib, BevacizumabIFN, Sorafenib) approved as ﬁrst-line treatment for 
mRCC in Colombia. METHODS: A Markov model was developed using 6-week 
cycles from a third-party payer perspective and a 5-year time-line; it also presumed 
that all the patients (pts) continued with active treatment until progression when it 
became acceptable to continue with a second-line treatment or best supportive care 
(BSC). Overall survival (OS) and progression-free survival (PFS) curves of IFN were 
used as reference framework; they were obtained form a published clinical trial. The 
hazard ratios (HR) for PFS and OS were estimated for comparing new generation 
medicaments with IFN. The information about frequency of use and health service 
cost units consumed in Colombia was taken from a series of 24 pts treated in 4 cities. 
Service costs were requested from an external consultant and corresponded to the 
average value billed by the EPSs, calculated from 33 sources of information which 
were representative of the country’s market. The cost of the medicaments was obtained 
from LCLC. The costs and beneﬁts were discounted annually at 3%. RESULTS: 
Sunitinib treatment was associated with a gain in life years (LY) saved, the Incremental 
cost analysis indicated a difference of 41.1 million Col$ (19,773 USD) in the average 
total cost of treatment when Sunitinib was compared to IFN; in contrast, comparing 
Sorafenib and BevacizumabINF to Sunitinib demonstrated that the average total cost 
was less for the Sunitinib by 8.3 (3,991 USD) and 104.2 million Col$ (50,155 USD), 
respectively. Additionally, the ICER by life years (LY) gained demonstrated Sunitinib’s 
simple dominance over Sorafenib and the combination of BevacizumabIFN, and 
an average by LY gained of 100.5 million Col$ (48,362 USD) compared to IFN. 
CONCLUSIONS: Sunitinib is the most cost-effective option as ﬁrst-line treatment for 
mRCC pts in Colombia.
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OBJECTIVES: Dasatinib 100 mg is the optimized and recommended initial dose for 
patients with CML in chronic phase in Mexico. However, little is known on its cost 
effectiveness when compared with recent treatment alternatives in the market such as 
nilotinib 800 mg. This study addresses this question under the Mexican health care 
perspective. METHODS: A cost utility life-time Markov model based was used to 
calculate the incremental cost per Quality Adjusted Life Year (QALY) of the compared 
therapies. The model follows patients with CML in CP considering the different phases 
of the disease progression including accelerated and blast health states. Initial best 
response as deﬁned by the START (SRC/ABL Tyrosine Kinase Inhibition Activity 
Research Trials) studies determined the pathway the patients will follow within the 
model. The researchers did not identify any clinical trials that compared dasatinib 
directly with the comparator, and therefore an indirect comparison was performed. 
For the indirect comparison all the relevant published efﬁcacy literature was used. 
Transition probabilities and QALYs were estimated from published international lit-
erature. Estimates of the use of health care resources by CML patients in Mexico came 
from a previously reported study using the Delphi Panel technique. Costs of drugs and 
other health care treatments were primarily obtained from IMSS published informa-
tion and discounted at 5% (using the recent published guidelines by the Mexican 
National Health Council). Sensitivity analysis was performed. RESULTS: The eco-
nomic evaluation revealed that dasatinib was more effective (QALY difference of 0.2) 
and less costly (-US$41,329) than nilotinib therapy. These ﬁndings were robust to 
deterministic sensitivity analysis. CONCLUSIONS: In México, Dasatinib is a cost 
effective therapy for the management of Imatinib resistant patients with CML in the 
chronic phase. Collection of long term health care efﬁcacy data will help to validate 
these results.
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OBJECTIVES: To analyze the cost-effectiveness of temozolomide in the treatment of 
newly diagnosed glioblastoma multiforme versus radiotherapy alone from the Mexican 
health care perspective METHODS: A cost-effectiveness analysis was performed based 
on a Markov model, with three health states: initial, disease progression and death. 
This model allowed us to compare the expected outcomes and costs associated with 
temozolomide compared with radiotherapy alone for a synthetic cohort of patients 
aged q55 years over a 5-year period. The model cycles every 6 months and continues 
until all patients die. The probabilities of transition between health states were 
obtained from the literature. Costs were expressed in 2008 US dollar. Outcome esti-
mates included the incremental cost-effectiveness ratio (ICER) and cost per life-year 
(LY) gained. Second-order Monte Carlo simulations were undertaken in which values 
were randomly drawn from distributions of these parameters. RESULTS: The accu-
mulated discounted effect is 1.03 LY per patient receiving temozolomide compared to 
0.93 LY for radiotherapy alone. Total lifetime medical cost was US$31,698 for 
temozolomide vs. US$30,715 for radiotherapy alone. The incremental cost-effective-
ness of temozolomide was $US 983 per life year gained. There is a 70% probability 
that temozolomide is cost-effective at a US$10,000 per life-year saved threshold and 
a slightly more than 95% probability of being cost-effective at a US$18,000 per life-
year saved threshold CONCLUSIONS: Results from these analyses suggest that in the 
Mexican setting, use of temozolomide in place of radiotherapy alone for treatment of 
glioblastoma multiforme is likely to be cost saving. These conclusions are supported 
by the use of conservative assumptions and sensitivity analyses.
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OBJECTIVES: To estimate the cost, clinical implications and cost-effectiveness of 
different screening strategies for the early detection and prevention of breast cancer 
in Colombia, that is a growing health problem in Colombia. METHODS: The course 
of women aged 40 and older who are at risk of developing breast cancer and are eli-
gible to be screened for early detection and prevention was modeled using discrete 
event simulation. Six identical cohorts of 10,000 women were simulated 100 times, 
to compare 6 different screening strategies. Age distribution of the population was 
obtained from national data in Colombia, and the risk of developing cancer was based 
on the 1998–2002 breast cancer incidence rates in Cali, Colombia. Disease progression 
parameters for women who develop cancer were obtained from published data. Only 
direct medical costs were considered; costs are reported in 2008 Colombian Pesos 
(COP) and inﬂated using the Consumer Price Index (CPI) where current costs were 
not available. Costs and life years gained were discounted at a 3% rate. Main sensitiv-
ity analyses were around the sensitivity of the mammography and the breast clinical 
exam, the breast cancer incidence rates. RESULTS: The most cost-effective strategy 
for Colombia is an opportunistic screening program with biannual mammography for 
women between 50 and 69 years and annual breast clinical exam for women between 
30 and 69 years, with a cost per life year gained per woman of COP 36,984 and a 
reduction of 28.68% in the number of cases of cancer that progress to fatal stages of 
the disease, compared with the do-nothing strategy. CONCLUSIONS: Opportunistic 
screening for breast cancer is expected to improve outcomes and save costs compared 
to the other 5 strategies. Thus, it will bring better health to Colombian women at risk 
of developing or suffering from breast cancer at a savings to the Health Authorities.
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OBJECTIVES: Due to their commonality, basal cell carcinoma can be an expensive 
cancer to manage. Imiquimod is an effective treatment for superﬁcial basal cell carci-
noma (sBCC) though cost efﬁcacy studies are lacking. This study compared the costs 
of management approaches for superﬁcial basal cell carcinoma from a third party 
perspective at 1 and 5 years. METHODS: A decision analytic model was developed 
that compared cost of imiquimod treatment versus commonly used surgical interven-
tions including surgical excision and simple excision, curettage and electrodesiccation(ED 
& C). A United States third party payer perspective was used for the analysis. Pub-
lished recurrence rates and Medicare reimbursement rates were used for modeling and 
sensitivity analyses. RESULTS: The expected ﬁve-year modeling for imiquimod 
A496 Rio Abstracts
revealed a cost of US $1438 compared to $1074 and $888 for simple excision and 
ED& C respectively. Sensitivity analysis using probability of recurrence had little 
impact on the base case cost modeling with imiquimod falling between ED & C and 
simple excision. CONCLUSIONS: The overall cost of therapy of sBCC by topical 
imiquimod was slightly higher compared to the common ofﬁce-based surgical treat-
ments. Preferences for number of visits, cosmetic outcome, risks of surgery, side effects 
of topical treatment all need to be considered on an individual basis.
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OBJECTIVES: The second line options for patients with GIST on imanitib 400 mg/ 
day, whose tumor continued to progress is: imatinib dose increased to 600 mg/day 
followed by another increase to 800 mg/day. In case of intolerance, only palliative 
treatment was available. In these cases, TTP was not higher than 6.4 weeks. Sunitinib 
malate consists of a new therapeutic alternative for this unmet medical need. The 
objective of this economic evaluation was to estimate the costs and outcomes for GIST 
treatment with sunitinib, compared with best supportive care (BSC) and imatinib 
800 mg/day, under the Brazilian public health care system perspective METHODS: A 
Markov model was developed, with a maximum of 6 years time horizon, to simulate 
the costs and outcomes associated to GIST treatment, considering health care resources 
from the Brazilian Public Health Care System perspective (SUS). The model considers 
disease progression, death from all causes, adverse events and dose decrease needs 
every 6 weeks cycles. Results were expressed as life-years (LY) gained, progression-free 
LY (PFLY) gained, treatment costs, and incremental cost-effectiveness ratios (ICER) 
RESULTS: In comparison with BSC, sunitinib increases LY and PFLY by 0.3 and 
0.26 years respectively, with incremental costs of R$86,756 (US$61,968 Purchasing 
Power Parity 2005, 1US$  1,4R$) In comparison with imatininb, sunitinib was both 
more effective (with 0.02 LY and 0.47 PFLY gained) and less costly over 6 years. 
CONCLUSIONS: This model suggests that when taking the perspective of the Brazil-
ian Public Health Care System (SUS), sunitinib is a cost-effective alternative when 
compared with imatinib 800 mg/day in a 6 years time horizon. In comparison to BSC, 
sunitinib promoted better results on efﬁcacy parameters, with an incremental cost in 
the same time horizon.
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OBJECTIVES: To assess the incremental cost effectiveness ratio (ICER) of Clofarabine 
for the treatment of pediatric patients 1 to 21 years old with refractory or relapsed 
acute leukemias compared against the usual care in this patient group. METHODS: 
A decision tree model of the outcomes of Clofarabine compared against the usual care 
was constructed to estimate the cost-effectiveness of a hypothetical cohort of pediatric 
patients 1 to 21 years old with refractory or relapsed acute leukemia. The results of 
clinical trail (CLO 212) were used to create a model of disease progression and treat-
ment patterns. The analysis was performed from the Mexican Health Care System 
perspective, only direct costs were considered and all costs were reported in 2008 
Mexican pesos. Extensive sensitivity and variability analyses were performed to test 
the robustness of the cost-effectiveness results. RESULTS: Life expectancy was greater 
for clofarabine than usual supportive care; 3.04 and 0.37 years, respectively. Total 
lifetime medical cost was US$63,938 for clofarabine and US$6,475 for best supportive 
care. The incremental cost-effectiveness of clofarabine was US$21,528 per life year 
gained. Considering a willingness to pay (WTP) threshold of S21,800 “3 GDP” per 
LY, there is a 90% probability that treatment with clofarabine is cost-effective relative 
to best supportive care treatment. Sensitivity analyses showed that drug cost acquisi-
tion, age, discount rate most affected estimates of cost-effectiveness CONCLUSIONS: 
We estimated the ICER for clofarabine compared to usual care at approximately $ 
21,528 per life year gained in the treatment of acute lymphoblastic leukemia in 
Mexico. This ratio may well be in range of what is acceptable and warrants reimburse-
ment for new drug treatments in the Mexico, in particular in therapeutic areas as 
end-stage oncology and HIV and other last-resort health care interventions.
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OBJECTIVES: To assess cost effectiveness of Letrozole vs Tamoxifen in ﬁve-year 
adjuvant treatment of hormone receptor-positive, post-menopausal early breast cancer 
patients in Colombia. METHODS: The natural history of the disease and the effects 
of treatment were modeled as a Markov process. Effectiveness was deﬁned as disease-
free survival. Transition probabilities for the disease and adverse effects were obtained 
from the literature. Costs are the median of actual costs for some health insuring ﬁrms 
and the National Cancer Institute, and are expressed in 2007 Colombian pesos (COP). 
Sensibility analysis were also carried out for costs, effectiveness, discount and model 
assumptions. RESULTS: Compared to Tamoxifen, Letrozole results in an additional 
relapse-free period of 0.45 years. Each year obtained in this way costs $58,128,304 
(COP), or $79,355,466 (COP) with a discount rate of 3%. The results were not sensi-
tive to relapse cost, adverse events and discount. Drug cost was the main variable that 
affected cost effectiveness: Letrozole is cost effectiveness for Colombia if its cost is 
lower than $2081 (COP) per tablet. CONCLUSIONS: The use of Letrozole has an 
additional cost per relapse-free year over the Colombian per capita GDP ($7,521,363 
(COP) in 2007). Hence, for postmenopausal, early breast cancer hormone receptor 
positive women in Colombia, the cost-effective alternative is Tamoxifen as adjunvant 
therapy for ﬁve years.
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OBJECTIVOS: Determinar si en pacientes aﬁliadas al sistema de salud colombiano 
que asisten al Instituto Nacional de Cancerología, con cáncer de mama temprano y 
sobreexpresión del marcador Her2-neu, es costo efectivo el uso de trastuzumab como 
terapia adyuvante, desde el punto de vista del pagador. METODOLOGÍAS: Se realizó 
un estudio de costo-efectividad empleando un modelo de Markov, con la perspectiva 
del pagador, horizonte de tiempo la expectativa de vida de las mujeres colombianas 
y tasa de descuento 3%. Se construyó un modelo de historia natural de la enfermedad, 
se establecieron los costos para los diferentes escenarios usando el manual tarifario 
SOAT del Ministerio de la Protección Social, para el año 2008. RESULTADOS: El 
costo del tratamiento adyuvante sin trastuzumab es $9,396,220. El costo del trata-
miento adyuvante con Trastuzumab es $126,380,645. El costo de la ICC aguda 
inducida por trastuzumab es $2,252,600 y la ICC crónica $863,520. El uso de trastu-
zumab adyuvante durante un año, produce una relación de costo efectividad de 
$39,516,226 sin descuento y $58,090,827 con descuento por cada año de vida 
ganado. El análisis de sensibilidad muestra una relación costo efectividad favorable si 
se usa por periodos menores a un año, siempre y cuando se mantenga lae efectividad 
y el paciente logre vivir por lo menos diez años. CONCLUSIONES: Trastuzumab es 
un medicamento de efectividad comprobada en la terapia adyuvante, en Colombia el 
costo de un año de tratamiento adyuvante contrasta con el PIB percapita de US$3729, 
este estudio sugiere que para una mayor eﬁciencia de los medicamentos innovadores 
estos deben tener costos que permitan su acceso en los países de ingresos bajos, por 
tanto se sugiere el aprobación de nuevo medicamentos con precios preferenciales para 
estos países.
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OBJECTIVES: To compare the cost-effectiveness of Palonosetron in the Prevention 
of Chemotherapy-Induced Nausea and Vomiting (CINV) Associated with Highly 
Emetogenic Chemotherapy METHODS: A decision analytic model was used to syn-
thesise the health care costs and beneﬁt of a Palonosetron regimen versus Ondansetron 
over a ﬁve days period. The main effectiveness measure was “complete response CR”, 
deﬁned as the percentage of patients who had neither emesis nor rescue therapy over 
the 5-day cycle, was derived from a previously published clinical trial. Uncertainty in 
the data parameters was investigated through a series of one-way sensitivity analyses, 
simulation methods and scenario analyses. The analysis was conducted from the 
Mexican health care perspective using 2008 unit cost prices RESULTS: The corre-
sponding health effects were 0.69 CR for Palonosetron and 0.48 CR for Ondansetron 
regimen. The mean total cost of the Palonosetron regimen was US$77.45 compared 
with $US 58.09 for the Ondansetron regimen. The cost of successfully treating one 
patient with Palonosetron and Ondansetron was US$94.18.87 and US$111.73, respec-
tively. The incremental cost-effectiveness ratio was $US 94.18 per CR gained for 
Palonosetron over the 5-day period. Findings were robust across various sensitivity 
analyses CONCLUSIONS: The results indicate that Palonosetron is a more cost-
 effective antiemetic compared with Ondansetron for the prevention of CINV associ-
ated with highly emetogenic chemotherapy. The incidence of CINV and use of rescue 
antiemetics was signiﬁcantly greater in the Ondansetron group compared with the 
Palonosetron group.
